Gene Therapy for SADS: Is this the New Holy Grail? (Joint Session)

Description

The session will cover new gene therapies on the horizon or in clinical trial investigations for genetic channelopathies and cardiomyopathies. A joint session with The SADS (Sudden Arrhythmia Death Syndromes) Foundation.

Learning Objectives

Describe gene therapy, its history, and how recent research shows it may be delivered to patients with arrhythmogenic cardiomyopathy.
Demonstrate an understanding of the genetic variants which are associated with development of cardiomyopathies and channelopathies and how therapies for gene-specific conditions are on the horizon.
Identify updated therapies in the management of patients with channelopathies and cardiomyopathies.

Session Chair(s)

Marina Cerrone, MD
Martin Tristani-Firouzi, MD

Presentation

Where Are We With Gene Therapy in 2025?
Presenter(s): Andrew Paul. Landstrom, MD, PhD

Don't Forget About Traditional Therapies: Recent Advances in the Management of SADS Conditions
Presenter(s): Michael John. Ackerman, MD, PhD

What Do MDs Need to Know?
Presenter(s): Gregory Webster, MD, MPH

Looking to the Future: Where Will We Be in 2035?
Presenter(s): Patrick T. Ellinor, MD, PhD

Disclosures

Andrew Landstrom:

Nothing Relevant to Disclose

Michael Ackerman:

AliveCor (Intellectual Property Rights - Consulting)
Boston Scientific (Honoraria/Speaking/Consulting Fee - Consulting)
Medtronic (Honoraria/Speaking/Consulting Fee - Consulting)
UpToDate, Inc. (Honoraria/Speaking/Consulting Fee - Consulting)
ARMGO Pharma (Honoraria/Speaking/Consulting Fee - Consulting)
Abbott (Honoraria/Speaking/Consulting Fee - Consulting)
Bristol-Myers Squibb (Honoraria/Speaking/Consulting Fee - Consulting)
Anumana (Intellectual Property Rights - Consulting)
Pfizer, Inc. (Intellectual Property Rights - Consulting)
Tenaya Therapeutics (Honoraria/Speaking/Consulting Fee - Consulting)
Thryv Therapeutics (Royalty Income - Consulting)
BioMarin, Inc (Honoraria/Speaking/Consulting Fee - Consulting)
Illumina (Honoraria/Speaking/Consulting Fee - Consulting)
Solid Biosciences (Honoraria/Speaking/Consulting Fee - Consulting)
Prolaio (Honoraria/Speaking/Consulting Fee - Consulting)

Gregory Webster:

Nothing Relevant to Disclose

Patrick Ellinor:

Bayer Healthcare Pharmaceuticals (Honoraria/Speaking/Consulting Fee - Consulting)
Bayer Healthcare Pharmaceuticals (Research (Contracted Grants for PIs and Named Investigators only) - Research)
NovoNordisk (Research (Contracted Grants for PIs and Named Investigators only) - Research)
BMS / Pfizer Alliance (Research (Contracted Grants for PIs and Named Investigators only) - Research)

To view all Heart Rhythm 2025 Faculty Disclosures, please click here.

Education Framework

Ventricular Tachyarrhythmias
-- Ventricular Tachycardia (VT) - Antiarrhythmic Medications
-- 178. Know when to recommend antiarrhythmic medications for patients with ventricular arrhythmias and how to select the most appropriate drug considering the patient’s age and comorbidities, including during pregnancy.

Summary

Availability:

No future session

Cost:

FREE

Credit Offered:

No Credit Offered

Recommended

Abstract Catalog 2025: ePosters

FREE